Skip to main content
Erschienen in: Diabetologia 9/2004

01.09.2004 | Article

Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in Type 2 diabetic men with and without coronary heart disease

verfasst von: S. G. Wannamethee, G. D. O. Lowe, A. G. Shaper, A. Rumley, L. Lennon, P. H. Whincup

Erschienen in: Diabetologia | Ausgabe 9/2004

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

We have examined markers of haemostasis and inflammation in men with diabetes, coronary heart disease (CHD) or both, and assessed their associations with insulin resistance in men with Type 2 diabetes.

Methods

The study was carried out in 4066 British men aged 60 to 79 years who were not on warfarin or insulin, of whom there were 426 men with prevalent Type 2 diabetes and 842 with prevalent CHD.

Results

Men with Type 2 diabetes were more likely to have multiple risk factors and higher levels of haemostatic and inflammatory markers than men without, irrespective of CHD status. Compared with men with CHD only, men with diabetes only showed increased levels of tissue plasminogen activator antigen, increased plasma and blood viscosity, and increased levels of coagulation factors VII, VIII and IX. They also had dyslipidaemia. In men with diabetes, increased insulin resistance (homeostasis model assessment, HOMA) was associated with increased levels of haemostatic markers and dyslipidaemia. The prevalence of CHD increased significantly with increasing tertiles of HOMA (adjusted odds ratio 1.32 [95% CI: 0.72–2.42] in the second, and 1.70 [95% CI: 0.92–3.44] in the third tertile; p=0.04 for trend).

Conclusions/interpretation

Increased insulin resistance among men with Type 2 diabetes is associated with increased prevalence of CHD and of activated haemostasis and dyslipidaemia. Reducing insulin resistance in men with diabetes may reduce their tendency to develop thrombosis and hence CHD risk.
Literatur
1.
Zurück zum Zitat Kannel WB, McGee DL (1979) Diabetes and glucose tolerance as risk factors for CVD: the Framingham study. Diabetes Care 2:120–126PubMed Kannel WB, McGee DL (1979) Diabetes and glucose tolerance as risk factors for CVD: the Framingham study. Diabetes Care 2:120–126PubMed
2.
Zurück zum Zitat Haffner SM, Lehto S, Ronnema T et al. (1998) Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234CrossRefPubMed Haffner SM, Lehto S, Ronnema T et al. (1998) Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234CrossRefPubMed
3.
Zurück zum Zitat Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB (2002) The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol 40:954–960CrossRefPubMed Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB (2002) The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol 40:954–960CrossRefPubMed
4.
Zurück zum Zitat Lotufo PA, Gaziano M, Chae CU et al. (2001) Diabetes and all cause and coronary heart disease mortality among US Male Physicians. Arch Intern Med 161:242–247 Lotufo PA, Gaziano M, Chae CU et al. (2001) Diabetes and all cause and coronary heart disease mortality among US Male Physicians. Arch Intern Med 161:242–247
5.
Zurück zum Zitat Becker A, Bos G, de Vegt F et al. (2003) Cardiovascular events in Type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease: 10-year follow-up of the Hoorn Study. Eur Heart J 24:1406–1413CrossRefPubMed Becker A, Bos G, de Vegt F et al. (2003) Cardiovascular events in Type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease: 10-year follow-up of the Hoorn Study. Eur Heart J 24:1406–1413CrossRefPubMed
6.
Zurück zum Zitat Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA 287:2570–2581CrossRefPubMed Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA 287:2570–2581CrossRefPubMed
7.
Zurück zum Zitat Carr ME (2001) Diabetes mellitus: a hypercoagulable state. J Diabetes Compl 15:44–54CrossRef Carr ME (2001) Diabetes mellitus: a hypercoagulable state. J Diabetes Compl 15:44–54CrossRef
8.
Zurück zum Zitat Schneider DJ, Nordt TK, Sobel BE (1993) Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 42:1–7PubMed Schneider DJ, Nordt TK, Sobel BE (1993) Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 42:1–7PubMed
9.
Zurück zum Zitat Haffner SM, Rewers M, D’Agostino R et al. (1999) Insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 22:562–568PubMed Haffner SM, Rewers M, D’Agostino R et al. (1999) Insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 22:562–568PubMed
10.
Zurück zum Zitat Inchiostro S, Bertoli G, Zanette G, Donadon V (1994) Evidence of higher insulin resistance in NIDDM patients with ischemic heart disease. Diabetologia 137:597–603CrossRef Inchiostro S, Bertoli G, Zanette G, Donadon V (1994) Evidence of higher insulin resistance in NIDDM patients with ischemic heart disease. Diabetologia 137:597–603CrossRef
11.
Zurück zum Zitat Yudkin JS (1999) Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent. Diabetes Care 22 [Suppl 3]:C25–C30 Yudkin JS (1999) Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent. Diabetes Care 22 [Suppl 3]:C25–C30
12.
Zurück zum Zitat Kohler HP (2002) Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly 132:241–252PubMed Kohler HP (2002) Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly 132:241–252PubMed
13.
Zurück zum Zitat Meigs JB, Mittleman MA, Nathan DM et al. (2000) Hyperinsulinemia, hyperglycemia, and impaired hemostasis. JAMA 283:221–228CrossRefPubMed Meigs JB, Mittleman MA, Nathan DM et al. (2000) Hyperinsulinemia, hyperglycemia, and impaired hemostasis. JAMA 283:221–228CrossRefPubMed
14.
Zurück zum Zitat Marques-Vidal P, Mazoyer E, Bongard V et al. (2003) Prevalence of insulin resistance syndrome in Southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 25:1371–1377 Marques-Vidal P, Mazoyer E, Bongard V et al. (2003) Prevalence of insulin resistance syndrome in Southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 25:1371–1377
15.
Zurück zum Zitat Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction. Arterioscler Thromb Vasc Biol 19:972–978PubMed Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction. Arterioscler Thromb Vasc Biol 19:972–978PubMed
16.
Zurück zum Zitat Festa A, D’Agostino R, Howard G, Mykkanen L, Tracey RP, Haffner S (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42–47PubMed Festa A, D’Agostino R, Howard G, Mykkanen L, Tracey RP, Haffner S (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42–47PubMed
17.
Zurück zum Zitat Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ (1981) British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. BMJ 283:179–186PubMed Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ (1981) British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. BMJ 283:179–186PubMed
18.
Zurück zum Zitat Walker M, Shaper AG, Lennon L, Whincup PH (2000) Twenty years follow-up of a cohort based in general practices in 24 British towns. J Public Health Med 22:479–485CrossRefPubMed Walker M, Shaper AG, Lennon L, Whincup PH (2000) Twenty years follow-up of a cohort based in general practices in 24 British towns. J Public Health Med 22:479–485CrossRefPubMed
19.
Zurück zum Zitat Wannamethee SG, Lowe GDO, Whincup PH, Rumley A, Walker M, Lennon L (2002) Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 105:1785–1790CrossRefPubMed Wannamethee SG, Lowe GDO, Whincup PH, Rumley A, Walker M, Lennon L (2002) Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 105:1785–1790CrossRefPubMed
20.
Zurück zum Zitat Emberson J, Whincup PH, Walker M, Thomas M, Alberti KGMM (2002) Biochemical measures in a population based study: the effect of fasting duration and time of day. Ann Clin Biochem 39:493–501 Emberson J, Whincup PH, Walker M, Thomas M, Alberti KGMM (2002) Biochemical measures in a population based study: the effect of fasting duration and time of day. Ann Clin Biochem 39:493–501
21.
Zurück zum Zitat Whincup PH, Bruce NG, Cook DG, Shaper AG (1992) The Dinamap 1846SX automated blood pressure recorder: comparison with the Hawksley random zero sphygmomanometer under field conditions. J Epidemiol Comm Health 46:164–169 Whincup PH, Bruce NG, Cook DG, Shaper AG (1992) The Dinamap 1846SX automated blood pressure recorder: comparison with the Hawksley random zero sphygmomanometer under field conditions. J Epidemiol Comm Health 46:164–169
22.
Zurück zum Zitat Bruce NG, Cook DG, Shaper AG (1990) Differences between observers in blood pressure measurement with an automatic oscillometric recorder. J Hypertens Suppl 8:S11–S13 Bruce NG, Cook DG, Shaper AG (1990) Differences between observers in blood pressure measurement with an automatic oscillometric recorder. J Hypertens Suppl 8:S11–S13
23.
Zurück zum Zitat Trinder P (1969) Determination of blood glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 6:24–27 Trinder P (1969) Determination of blood glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 6:24–27
24.
Zurück zum Zitat Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME (1993) Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 39:578–582 Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME (1993) Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 39:578–582
25.
Zurück zum Zitat Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiana F, Zenere MB (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 23:57–63PubMed Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiana F, Zenere MB (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 23:57–63PubMed
26.
Zurück zum Zitat Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 385:2486–2497 Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 385:2486–2497
27.
Zurück zum Zitat Danesh J, Collins R, Peto R, Lowe GDO (2000) Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J 21:515–520CrossRefPubMed Danesh J, Collins R, Peto R, Lowe GDO (2000) Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J 21:515–520CrossRefPubMed
28.
Zurück zum Zitat Pouliot MC, Despres JP, Lemieux S et al. (1994) Waist circumference and abdominal saggital diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 73:460–468CrossRefPubMed Pouliot MC, Despres JP, Lemieux S et al. (1994) Waist circumference and abdominal saggital diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 73:460–468CrossRefPubMed
29.
Zurück zum Zitat Seligman BGS, Gross JL, Biolo A, Clausell NC, Polanczyk CA (2000) Increased plasma levels of endothelin 1 and von Willebrand Factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care 23:1395–1400PubMed Seligman BGS, Gross JL, Biolo A, Clausell NC, Polanczyk CA (2000) Increased plasma levels of endothelin 1 and von Willebrand Factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care 23:1395–1400PubMed
30.
Zurück zum Zitat Danesh J, Collins R, Appleby P et al. (1998) Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279:1477–1482CrossRefPubMed Danesh J, Collins R, Appleby P et al. (1998) Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279:1477–1482CrossRefPubMed
31.
Zurück zum Zitat Danesh J, Whincup P, Walker M et al. (2001) Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 103:2323–2327PubMed Danesh J, Whincup P, Walker M et al. (2001) Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 103:2323–2327PubMed
32.
Zurück zum Zitat Whincup PH, Danesh J, Walker M et al. (2002) Von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 23:1764–1770CrossRefPubMed Whincup PH, Danesh J, Walker M et al. (2002) Von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 23:1764–1770CrossRefPubMed
33.
Zurück zum Zitat Lowe GDO, Danesh J, Lewington S et al. (2004) Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta-analysis. Eur Heart J 25:252–259CrossRefPubMed Lowe GDO, Danesh J, Lewington S et al. (2004) Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta-analysis. Eur Heart J 25:252–259CrossRefPubMed
34.
Zurück zum Zitat Jager A, van Hinsbergh VWM, Kostense PJ et al. (1999) von Willebrand Factor, C-reactive protein, and 5 year mortality in diabetic and non-diabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 19:3071–3078PubMed Jager A, van Hinsbergh VWM, Kostense PJ et al. (1999) von Willebrand Factor, C-reactive protein, and 5 year mortality in diabetic and non-diabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 19:3071–3078PubMed
36.
Zurück zum Zitat Lowe GDO, Haverkate F, Thompson SG et al., on behalf of the ECAT DVT Study Group (1999) Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and hemostatic variables: the ECAT DVT Study. Thromb Haemostas 81:879–886 Lowe GDO, Haverkate F, Thompson SG et al., on behalf of the ECAT DVT Study Group (1999) Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and hemostatic variables: the ECAT DVT Study. Thromb Haemostas 81:879–886
37.
Zurück zum Zitat Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG (2000) Non-traditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerotic Risk in Communities (ARIC) Study. Ann Intern Med 133:81–91PubMed Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG (2000) Non-traditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerotic Risk in Communities (ARIC) Study. Ann Intern Med 133:81–91PubMed
38.
Zurück zum Zitat Matsumoto K, Sera Y, Abe Y, Ueka Y, Tominaga T, Miyake S (2003) Inflammation and insulin resistance are independently related to all-cause death and cardiovascular events in Japanese patients with type 2 diabetes. Atherosclerosis 169:317–321CrossRefPubMed Matsumoto K, Sera Y, Abe Y, Ueka Y, Tominaga T, Miyake S (2003) Inflammation and insulin resistance are independently related to all-cause death and cardiovascular events in Japanese patients with type 2 diabetes. Atherosclerosis 169:317–321CrossRefPubMed
39.
Zurück zum Zitat Lowe GDO, Yarnell JWG, Rumley A, Bainton D, Sweetnam PM (2001) C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell Study. Are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 21:603–610PubMed Lowe GDO, Yarnell JWG, Rumley A, Bainton D, Sweetnam PM (2001) C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell Study. Are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 21:603–610PubMed
40.
Zurück zum Zitat Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U (2000) Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von-Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscl Thromb Vasc Biol 20:2019–2023PubMed Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U (2000) Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von-Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscl Thromb Vasc Biol 20:2019–2023PubMed
41.
Zurück zum Zitat De Bono D (1994) Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. Br Heart J 71:504–507PubMed De Bono D (1994) Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. Br Heart J 71:504–507PubMed
42.
Zurück zum Zitat Haffner SM, Valdez RA, Hazuda HP et al. (1992) Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes 41:715–722PubMed Haffner SM, Valdez RA, Hazuda HP et al. (1992) Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes 41:715–722PubMed
43.
Zurück zum Zitat Haffner SM, D’Agostino R Jr, Festa A et al. (2003) Low insulin sensitivity (Si=0) in diabetic and nondiabetic subjects in the Insulin Resistance Atherosclerosis Study: is it associated with components of the metabolic syndrome and nontraditional risk factors? Diabetes Care 26:2796–2803PubMed Haffner SM, D’Agostino R Jr, Festa A et al. (2003) Low insulin sensitivity (Si=0) in diabetic and nondiabetic subjects in the Insulin Resistance Atherosclerosis Study: is it associated with components of the metabolic syndrome and nontraditional risk factors? Diabetes Care 26:2796–2803PubMed
44.
Zurück zum Zitat Bonora E, Perbellini S, Formentini G et al. (2002) HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Diabetes Care 25:1135–1141PubMed Bonora E, Perbellini S, Formentini G et al. (2002) HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Diabetes Care 25:1135–1141PubMed
45.
Zurück zum Zitat Lehto S, Ronnemaa T, Pyorala K, Laakso M (2000) Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type 2 diabetes. Diabetologia 43:148–155CrossRefPubMed Lehto S, Ronnemaa T, Pyorala K, Laakso M (2000) Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type 2 diabetes. Diabetologia 43:148–155CrossRefPubMed
46.
Zurück zum Zitat DeFronzo RA, Tobin JD, Andres R (1979) The glucose clamp technique: a method for the quantification of beta cell sensitivity to glucose and tissue sensitivity to insulin. Am J Physiol 237:E214–E223PubMed DeFronzo RA, Tobin JD, Andres R (1979) The glucose clamp technique: a method for the quantification of beta cell sensitivity to glucose and tissue sensitivity to insulin. Am J Physiol 237:E214–E223PubMed
47.
Zurück zum Zitat UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRefPubMed UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRefPubMed
Metadaten
Titel
Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in Type 2 diabetic men with and without coronary heart disease
verfasst von
S. G. Wannamethee
G. D. O. Lowe
A. G. Shaper
A. Rumley
L. Lennon
P. H. Whincup
Publikationsdatum
01.09.2004
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 9/2004
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1491-7

Weitere Artikel der Ausgabe 9/2004

Diabetologia 9/2004 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.